| Macular Degeneration (AMD) and Diabetic | | | | |
| Retinopathy Pharmaceutical Market 2010-2025 | | | | Our report examines prospects for the retinal |
| | | | | disorders market over the coming 15 years. The |
| - what does the future hold for drugs to treat | | | | commercial success of Lucentis in treating wet |
| those disorders? | | | | AMD illustrates the high rewards for successful |
| | | | | treatments. Our analyses reveal that there are |
| Our new report examines current and future | | | | commercial opportunities for the treatment of |
| prospects for the age-related macular | | | | geographic atrophy (advanced dry AMD) and for |
| degeneration (AMD) and diabetic retinopathy (DR) | | | | wet AMD, among other disorders. There is a need |
| pharmaceutical markets. The global market for | | | | for advantages over existing therapies, for |
| AMD and DR drugs exceeded $2.5bn in 2009, with | | | | improved clinical outcomes and ease of dosing. A |
| growth from previous years. We predict that the | | | | large potential market for pharmacological |
| overall market will expand from 2010 onwards. | | | | treatment of diabetic retinopathy, AMD and other |
| The rising prevalence of AMD and DR is due to | | | | retinal disorders exists. |
| aging populations worldwide and other changes. In | | | | |
| particular, the world is facing a "diabetes | | | | Un-met and under-met therapeutic needs |
| epidemic", with soaring numbers of people with | | | | provide an impetus to drug developers, with high |
| diabetes and related complications, including | | | | technological and commercial potential in this |
| diabetic retinopathy. ( ) | | | | sector, our study reveals. What impact will |
| | | | | monoclonal antibodies and steroid implants have |
| In particular, Macular Degeneration (AMD) and | | | | on the future market? Which products are most |
| Diabetic Retinopathy Pharmaceutical Market | | | | likely to meet therapeutic needs in future years? |
| 2010-2025 covers market prospects for the | | | | Can newer therapies compete successfully with |
| following agents: | | | | established treatments? How will Avastin affect |
| • Lucentis | | | | the market share of Lucentis, and what are the |
| • Visudyne | | | | implications for the future market? Our new |
| • Macugen | | | | report covers such questions, providing the |
| • Avastin. | | | | information that you need. |